Reviews/GLP-1 Receptor Agonists/Improve psoriasis severity
Novel · GLP1-NOV-05 · v2
Across this corpus, most studies that gave GLP-1 drugs to people who had both obesity and psoriasis reported that their skin disease scores went down. This includes two randomised trials [4][7] and two prospective follow-up studies [9][14], one of which was in obese patients who did not have diabetes [14], plus two single-patient reports of very large improvement [5][8]. The one study that tested the drug against a dummy injection in exactly the population the claim names, obese patients with normal blood sugar, found no meaningful difference in skin scores [3]. Much of the stronger evidence comes from patients who also had type 2 diabetes, so some of the skin benefit may come from better blood-sugar control rather than from the obesity side the claim is about. Because a consistent positive direction sits alongside that one null head-to-head test and a reliance on small, often uncontrolled studies, the panel did not treat the claim as settled.
Most included primary studies report PASI reductions on GLP-1 receptor agonist therapy in obese psoriasis patients: an open-label RCT in obese T2DM patients fell from a median PASI of 21 to 10 (p=0.002) [7], a prospective cohort in obesity with psoriasis fell from 10 to 5.1 (p<0.0001) [9], a cohort in a small diabetic obese group fell from 4.8 to 3.0 (P=0.03) [2], and a non-diabetic obesity cohort showed a 48% PASI reduction [14]. An RCT in psoriasis with T2DM reported significant PASI and DLQI improvement versus control [4], and two single-patient reports described 92% [5] and 98.3% [8] PASI reductions. The discordant result is the only placebo-controlled RCT in obese glucose-tolerant psoriasis [3], where PASI change was not significant versus placebo (P=0.228). The contested point: The evidence divides on whether a controlled, bias-resistant design in the exact claim population confirms benefit: the single placebo-controlled RCT in obese glucose-tolerant patients was null [3], while the positive controlled trials carry concurrent T2DM [4][7]. The open question is whether the benefit tracks the obesity axis the claim names or is mediated by glycaemic control.
All 16 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from GLP-1 Receptor Agonists, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The single placebo-controlled RCT in the exact claim population — obese but glucose-tolerant psoriasis [3] — found no significant PASI difference versus placebo (P=0.228), directly contradicting an unconditional improvement claim.
The strongest positive controlled trials [4] and [7] are in T2DM patients, so the PASI benefit may be mediated by glycaemic control rather than the obesity axis the claim specifies — population indirectness and confounding.
Where it remains uncertain. The one placebo-controlled RCT in obese glucose-tolerant psoriasis found no significant PASI change versus placebo (P=0.228) [3], and the strongest positive trials are in T2DM patients [4][7].
Aleatory
Clinical studies span only N=7 to N=43, so individual-patient variation dominates and point estimates are imprecise.
Epistemic
Only [3] is placebo-controlled in obese glucose-tolerant psoriasis, and it was null (P=0.228); no replication exists in this corpus.
The load-bearing papers from a corpus of 16, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Counter-evidence: the only placebo-controlled RCT in obese glucose-tolerant psoriasis found no significant PASI benefit, weakening the causal claim.
“no significant change in PASI was found in the liraglutide group (mean±standard deviation: -2.6 ± 2.1) compared with the placebo group (-1.3 ± 2.4) (P = 0.228)”
Panel auditInternal validity: medium · scope of inference: Obese but glucose-tolerant (non-diabetic) plaque psoriasis patients, PASI ≥8, over 8 weeks.Key limitations: small sample · short duration · glucose-tolerant only
Controlled RCT evidence of PASI improvement, though population is diabetic rather than obesity-defined.
“the change in the baseline value of PASI and DLQI in the treatment group showed a significant difference compared with the control group ( p < .05)”
Panel auditInternal validity: medium · scope of inference: Psoriasis patients with type 2 diabetes; obesity not characterized.Key limitations: small sample · obesity not reported · blinding unclear
Randomized (open-label) evidence of significant PASI improvement in obese T2DM psoriasis patients, N=31.
“the median baseline PASI score in patients treated with semaglutide was 21 (IQR = 19.8), while after 12 weeks of therapy the score was 10 (IQR = 6; p = 0.002)”
Panel auditInternal validity: medium · scope of inference: Obese type 2 diabetic psoriasis patients on background metformin, 12 weeks.Key limitations: open-label · small sample · diabetic population
Earliest on-claim cohort (N=7) in obese diabetic psoriasis showing significant PASI reduction.
“Liraglutide therapy decreased the median PASI from 4.8 to 3.0 (P = 0.03)”
Panel auditInternal validity: low · scope of inference: Obese diabetic psoriasis patients with relatively low baseline PASI (4.8).Key limitations: n=7 · no control group · confounded by weight and glycaemic change
4 of 16 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A consistent positive direction across small cohorts and two RCTs is offset by a null placebo-controlled RCT in the precise population and pervasive confounding by diabetes and uncontrolled design, placing confidence in the Uncertain band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Powered placebo-controlled RCT in non-diabetic obese psoriasis. The only placebo-controlled test in obese glucose-tolerant patients [3] was null and underpowered (N=20), leaving the exact claim population without a confirmatory controlled result. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A blinded, placebo-controlled RCT in obese, glucose-tolerant psoriasis patients, powered on PASI with a prespecified minimal clinically important difference.
Open question: Does GLP-1 receptor agonist therapy significantly improve PASI versus placebo in obese psoriasis patients without diabetes? Why it is still open: The only placebo-controlled RCT in glucose-tolerant obese patients [3] was null, and the non-diabetic positive evidence is an uncontrolled cohort [14].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19